ONK Therapeutics and NAYA Biosciences to assess proof-of-concept and establish activity and feasibility of the combination of ONK’s optimally engineered natural killer (NK) cell therapies and NAYA’s FLEX-NK™ bispecific antibodies for the treatment of cancerPartnership may be expanded to joint clinical development following successful completion of the initial researchCombination therapy expected to improve response rate and address significant unmet medical need in hepatocellular carcinoma (HCC) GALWAY, Ireland and SAN DIEGO and AVENTURA, Fla.

ONK Therapeutics和NAYA Biosciences评估概念验证，并建立ONK最佳工程自然杀伤（NK）细胞疗法和NAYA FLEX-NK联合使用的活性和可行性™在成功完成最初的研究联合治疗后，用于治疗癌症伙伴关系的双特异性抗体可能会扩展到联合临床开发，该联合治疗有望提高应答率，并解决爱尔兰戈尔韦和圣地亚哥以及佛罗里达州阿文图拉的肝细胞癌（HCC）未满足的医疗需求。

and SARASOTA, Fla., Dec. 06, 2023 (GLOBE NEWSWIRE) -- ONK Therapeutics (“ONK”), an innovative cell therapy company dedicated to developing the next generation of optimally engineered off-the-shelf natural killer (NK) cell therapies, and NAYA Biosciences Inc. ('NAYA'), a company dedicated to increasing patient access to breakthrough treatments in fertility, oncology, and regenerative medicine, today announced that they have entered into a research partnership to evaluate combination therapy consisting of ONK’s optimally-engineered natural killer (NK) cell therapies and NAYA’s FLEX-NK™ bispecific antibodies.

和佛罗里达州萨拉索塔，2023年12月6日（环球通讯社）--ONK Therapeutics（“ONK”），一家致力于开发下一代最佳工程现成自然杀伤（NK）细胞疗法的创新细胞疗法公司，以及NAYA Biosciences Inc.（“NAYA”），一家致力于增加患者获得生育，肿瘤学突破性治疗的公司，和再生医学，今天宣布他们已经建立了一个研究伙伴关系，以评估由ONK的最佳工程自然杀伤（NK）细胞疗法和NAYA的FLEX-NK组成的联合疗法™双特异性抗体。

Specifically, the partnership will explore the combination of ONK’s ONKT105, CISH + TGFβR2 double knock-out (KO), sIL-15 knock-in (KI) allogeneic NK cell therapy with NAYA’s GPC3-targeted NY-303 FLEX-NK™ bispecific antibody. “We are impressed with the data ONK has generated using its differentiated editing of NK cells, which may further enhance the efficacy of our FLEX-NK™ bispecific antibodies,” commented NAYA’s CEO Dr.

具体而言，该合作伙伴关系将探索ONK的ONKT105，CISH+TGFβR2双敲除（KO），sIL-15敲入（KI）同种异体NK细胞疗法与NAYA的GPC3靶向NY-303 FLEX-NK的组合™双特异性抗体。“ONK使用其对NK细胞的分化编辑产生的数据给我们留下了深刻的印象，这可能会进一步增强我们FLEX-NK的功效™双特异性抗体，”NAYA的首席执行官Dr。

Daniel Teper. “The future development of this combination therapy alongside our monotherapy clinical trials will help expand patient options and narrow the gap towards improving the long-term survival of patie.

丹尼尔·泰珀。“这种联合疗法的未来发展以及我们的单一疗法临床试验将有助于扩大患者的选择范围，缩小差距，以提高患者的长期生存率。